title: Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2.
abstract: The RV144 trial demonstrated 31% vaccine efficacy at preventing human immunodeficiency virus (HIV)-1 infection. Antibodies against the HIV-1 envelope variable loops 1 and 2 (Env V1 and V2) correlated inversely with infection risk. We proposed that vaccine-induced immune responses against V1/V2 would have a selective effect against, or sieve, HIV-1 breakthrough viruses. A total of 936 HIV-1 genome sequences from 44 vaccine and 66 placebo recipients were examined. We show that vaccine-induced immune responses were associated with two signatures in V2 at amino acid positions 169 and 181. Vaccine efficacy against viruses matching the vaccine at position 169 was 48% (confidence interval 18% to 66%; P = 0.0036), whereas vaccine efficacy against viruses mismatching the vaccine at position 181 was 78% (confidence interval 35% to 93%; P = 0.0028). Residue 169 is in a cationic glycosylated region recognized by broadly neutralizing and RV144-derived antibodies. The predicted distance between the two signature sites (21 ± 7 Å) and their match/mismatch dichotomy indicate that multiple factors may be involved in the protection observed in RV144. Genetic signatures of RV144 vaccination in V2 complement the finding of an association between high V1/V2-binding antibodies and reduced risk of HIV-1 acquisition, and provide evidence that vaccine-induced V2 responses plausibly had a role in the partial protection conferred by the RV144 regimen.
authors.affiliation: US Military HIV Research Program, Silver Spring, Maryland 20910, USA. mrolland@hivresearch.org
authors.forename: Morgane
authors.initials: M
authors.lastname: Rolland
authors.forename: Paul T
authors.initials: PT
authors.lastname: Edlefsen
authors.forename: Brendan B
authors.initials: BB
authors.lastname: Larsen
authors.forename: Sodsai
authors.initials: S
authors.lastname: Tovanabutra
authors.forename: Eric
authors.initials: E
authors.lastname: Sanders-Buell
authors.forename: Tomer
authors.initials: T
authors.lastname: Hertz
authors.forename: Allan C
authors.initials: AC
authors.lastname: deCamp
authors.forename: Chris
authors.initials: C
authors.lastname: Carrico
authors.forename: Sergey
authors.initials: S
authors.lastname: Menis
authors.forename: Craig A
authors.initials: CA
authors.lastname: Magaret
authors.forename: Hasan
authors.initials: H
authors.lastname: Ahmed
authors.forename: Michal
authors.initials: M
authors.lastname: Juraska
authors.forename: Lennie
authors.initials: L
authors.lastname: Chen
authors.forename: Philip
authors.initials: P
authors.lastname: Konopa
authors.forename: Snehal
authors.initials: S
authors.lastname: Nariya
authors.forename: Julia N
authors.initials: JN
authors.lastname: Stoddard
authors.forename: Kim
authors.initials: K
authors.lastname: Wong
authors.forename: Hong
authors.initials: H
authors.lastname: Zhao
authors.forename: Wenjie
authors.initials: W
authors.lastname: Deng
authors.forename: Brandon S
authors.initials: BS
authors.lastname: Maust
authors.forename: Meera
authors.initials: M
authors.lastname: Bose
authors.forename: Shana
authors.initials: S
authors.lastname: Howell
authors.forename: Adam
authors.initials: A
authors.lastname: Bates
authors.forename: Michelle
authors.initials: M
authors.lastname: Lazzaro
authors.forename: Annemarie
authors.initials: A
authors.lastname: O'Sullivan
authors.forename: Esther
authors.initials: E
authors.lastname: Lei
authors.forename: Andrea
authors.initials: A
authors.lastname: Bradfield
authors.forename: Grace
authors.initials: G
authors.lastname: Ibitamuno
authors.forename: Vatcharain
authors.initials: V
authors.lastname: Assawadarachai
authors.forename: Robert J
authors.initials: RJ
authors.lastname: O'Connell
authors.forename: Mark S
authors.initials: MS
authors.lastname: deSouza
authors.forename: Sorachai
authors.initials: S
authors.lastname: Nitayaphan
authors.forename: Supachai
authors.initials: S
authors.lastname: Rerks-Ngarm
authors.forename: Merlin L
authors.initials: ML
authors.lastname: Robb
authors.forename: Jason S
authors.initials: JS
authors.lastname: McLellan
authors.forename: Ivelin
authors.initials: I
authors.lastname: Georgiev
authors.forename: Peter D
authors.initials: PD
authors.lastname: Kwong
authors.forename: Jonathan M
authors.initials: JM
authors.lastname: Carlson
authors.forename: Nelson L
authors.initials: NL
authors.lastname: Michael
authors.forename: William R
authors.initials: WR
authors.lastname: Schief
authors.forename: Peter B
authors.initials: PB
authors.lastname: Gilbert
authors.forename: James I
authors.initials: JI
authors.lastname: Mullins
authors.forename: Jerome H
authors.initials: JH
authors.lastname: Kim
mesh_terms: D016915:AIDS Vaccines / Q000009:adverse effects / Q000276:immunology*; D020022:Genetic Predisposition to Disease; D015483:HIV Antibodies / Q000276:immunology; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control* / Q000821:virology*; D015497:HIV-1 / Q000235:genetics* / Q000276:immunology*; D006801:Humans; D008969:Molecular Sequence Data; D010802:Phylogeny; D016032:Randomized Controlled Trials as Topic; D017422:Sequence Analysis, DNA; D054299:env Gene Products, Human Immunodeficiency Virus / Q000235:genetics* / Q000276:immunology*
chemical_list: D016915:AIDS Vaccines; D015483:HIV Antibodies; D054299:env Gene Products, Human Immunodeficiency Virus